---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Dosing and administration questions"
description: "Dosing and administration questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Taking treatment, Dosing, and Administration. Questions: Can Trelegy be used as a rescue inhaler for COPD? What is the Trelegy dosage for COPD? What is the maximum dose of Trelegy for COPD? How many COPD patients used the Ellipta inhaler (Trelegy's device) correctly in a study? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Dosing and administration questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Dosing and administration questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta/dosing-and-administration).

## Taking treatment

<a id="trelegy-rescue-inhaler"></a>

### Can Trelegy be used as a rescue inhaler for COPD?

> “TRELEGY is NOT a rescue medication and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20is%20NOT%20a%20rescue,with%20an%20inhaled%2C%20short%2Dacting%20beta2%2Dagonist.)

> “If shortness of breath occurs in the period between doses, an inhaled, short-acting 
> beta2-agonist (rescue medicine, e.g., albuterol) should be used for immediate relief.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=3)

## Dosing

<a id="trelegy-dosage"></a>

### What is the Trelegy dosage for COPD?

> “The recommended dosage of TRELEGY ELLIPTA for maintenance treatment of COPD is 
> fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg (1 actuation of 
> TRELEGY ELLIPTA 100/62.5/25 mcg) once daily by oral inhalation.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=3)

> “TRELEGY 100/62.5/25 mcg is the only strength indicated for the treatment of COPD.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=TRELEGY%20100%2F62.5%2F25%20mcg%20is%20the,for%20the%20treatment%20of%20COPD.)

> “Take TRELEGY ELLIPTA as 1 inhalation, once daily, at the same time every day
> Use TRELEGY only once every 24 hours
> After inhalation, rinse the mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis
> Treat acute symptoms with an inhaled SABA such as albuterol”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Take%20TRELEGY%20ELLIPTA%20as%201,inhaled%20SABA%20such%20as%20albuterol)

<a id="trelegy-max-dose"></a>

### What is the maximum dose of Trelegy for COPD?

> “If TRELEGY ELLIPTA 100/62.5/25 mcg no longer controls symptoms of bronchoconstriction; 
> the patient’s inhaled, short-acting beta2-agonist becomes less effective; or the patient needs more 
> short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this 
> setting, re-evaluate the patient and the COPD treatment regimen at once. For COPD, the daily 
> dose of TRELEGY ELLIPTA 100/62.5/25 mcg should not be increased.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=6)

> “Do not use TRELEGY 
> ELLIPTA more than 1 time every 24 hours.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 2, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=2)

Note: The maximum recommended dosage of TRELEGY ELLIPTA 200/62.5/25 mcg in the label applies to asthma.

## Administration

<a id="trelegy-inhaler-correct-use"></a>

### How many COPD patients used the Ellipta inhaler (Trelegy's device) correctly in a study?

> “One study was conducted in patients with COPD (N=266)”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=One%20study%20was%20conducted%20in%20patients%20with%20COPD%20%28N%3D266%29)

This passage is in a collapsed section of the page; select: See study design

> “Inhalers did not contain active treatment.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Inhalers%20did%20not%20contain%20active%20treatment.)

This passage is in a collapsed section of the page; select: See study design

> “Both studies were 28-day, open-label, placebo studies designed to assess ease of use of the ELLIPTA inhaler among adult patients who used the inhaler correctly on Day 28.
>
> Correct use was evaluated using instructions derived from the prescribing information for products delivered in the ELLIPTA inhaler.
>
> At enrollment, patients were allowed up to 3 attempts to demonstrate correct use (with training between attempts 1 and 2, and 2 and 3, if necessary), and all patients were able to demonstrate correct use.
>
> On Day 28, patients were evaluated for correct use in a single attempt without additional instruction.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=Both%20studies%20were%2028%2Dday%2C%20open%2Dlabel%2C,single%20attempt%20without%20additional%20instruction.)

This passage is in a collapsed section of the page; select: See study design

> “In the COPD study, 97% of patients demonstrated correct use.”

Source: [TRELEGY ELLIPTA: Dosing & Delivery, captured 2026-11-14](https://www.trelegyhcp.com/dosing-and-delivery/#:~:text=In%20the%20COPD%20study%2C%2097%25%20of%20patients%20demonstrated%20correct%20use.)

This passage is in a collapsed section of the page; select: See study design

Note: The study used ELLIPTA inhalers without active ingredient. The page shows the share of patients who rated the inhaler easy to use in an image only.

<a id="trelegy-inspiratory-flow"></a>

### What inspiratory flow do very severe COPD patients reach through the Trelegy Ellipta inhaler?

> “At flow rates of 30, 60, and 90 L/min for 4 seconds under in 
> vitro test conditions, TRELEGY ELLIPTA delivers ≥90% of the target dose for each component.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=23)

> “In adult subjects with very severe COPD (FEV1/FVC [forced vital capacity] <70% and FEV1 
> <30% predicted), mean peak inspiratory flow through the ELLIPTA inhaler was 65.8 L/min 
> (range: 43.5 to 94.1 L/min).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=23)

> “The actual amount of drug delivered to the lung will depend on patient factors, such as 
> inspiratory flow profile.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=23)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
